Kendra Adams, Chief Financial Officer of C4 Therapeutics, Inc., filed a Statement of Changes in Beneficial Ownership on September 21, 2026, reporting two transactions in the company's common stock dated September 18, 2026.

Key Highlights

  • RSU vesting: 6,250 shares of common stock were acquired at $0 per share upon vesting of previously granted restricted stock units.
  • Tax withholding: 2,775 shares were withheld by C4 Therapeutics to satisfy tax obligations connected to the RSU settlement, at a price of $3.39 per share.
  • Resulting ownership: Adams directly holds 382,323 shares of common stock following the reported transactions.
  • Original RSU grant: The RSUs were initially reported in a filing by Adams on September 19, 2023.
  • No open-market sale: According to the filing, the share disposition "does not represent a sale by the Reporting Person."

RSU Settlement Details for C4 Therapeutics Chief Financial Officer

C4 Therapeutics, Inc. (NASDAQ:CCCC) is a biopharmaceutical company. According to the filing, CFO Kendra Adams reported two non-derivative transactions on September 18, 2026. The first, coded "M," reflects the acquisition of 6,250 shares of common stock at $0 per share upon the vesting and settlement of restricted stock units. The filing notes that this RSU grant was originally reported on September 19, 2023, meaning the units completed their vesting schedule in September 2026.

The second transaction, coded "F," records the disposition of 2,775 shares at $3.39 per share. The filing states explicitly that these shares were "withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs" and that the transaction "does not represent a sale by the Reporting Person." After both transactions, Adams directly and beneficially owns 382,323 shares of C4 Therapeutics common stock. The filing was signed by Shagha Russell as Attorney-in-Fact and submitted on September 21, 2026.

What Was Disclosed

The filing reported an RSU vesting event for C4 Therapeutics CFO Kendra Adams on September 18, 2026, resulting in 6,250 shares acquired and 2,775 shares withheld for taxes at $3.39 per share, leaving a direct beneficial ownership of 382,323 shares.